En Es
Categories

Industry News

Philips Collaborates with AI Startup Ibex to Accelerate Adoption of AI-Powered Digital Pathology Solutions

By Labmedica International staff writers
13 Apr 2021

Image: Philips Digital Pathology (Photo courtesy of Royal Philips)Royal Philips (Amsterdam, The Netherlands) and Ibex Medical Analytics (Tel Aviv, Israel) have entered into a strategic collaboration to jointly promote their digital pathology and AI solutions to hospitals, health networks and pathology labs worldwide.

The combination of Philips digital pathology solution (Philips IntelliSite Pathology Solution) and Ibex’s Galen AI-powered cancer diagnostics platform, currently in clinical use in Europe and the Middle East, empowers pathologists to generate objective, reproducible results, increase diagnostic confidence, and enable the productivity and efficiency improvements needed to cope with ever-increasing demand for pathology-based diagnostics. The announcement marks the latest extension to Philips’ AI-enabled Precision Diagnosis solutions portfolio, which leverages Philips and third-party AI solutions to deliver cutting-edge clinical decision support and optimized workflows that enable healthcare providers to deliver on the Quadruple Aim of better patient outcomes, improved patient and staff experiences, and lower cost of care.

The trend towards centralized pathology labs, the global shortage of trained pathologists, and increasing demands on histopathology posed by the growing number of cancer patients, leads pathology labs to actively seek efficiency-enhancing solutions that enable to maintain high accuracy levels. Digital pathology, enabled by solutions such as Philips IntelliSite Pathology Solution has already been shown to improve pathology lab productivity by 25%, while also allowing remote image reading by specialists and the immediate sharing of images with referring hospitals as part of comprehensive pathology reports. Ibex’s AI-powered Galen platform further streamlines workflow and improves accuracy via automated case prioritization, cancer heatmaps, grading and other productivity-enhancing tools.

Philips digital pathology solution is a comprehensive turnkey solution that helps to speed and simplify access to histopathology information across cancer care and beyond, supports full-scale digitization of histology in pathology labs and lab networks, and help increases workflow efficiency. At the heart is Philips IntelliSite Pathology Solution, which comprises an ultra-fast pathology slide scanner, an image management system and display, which includes advanced software tools to manage slide scanning, image storage, case review, and the sharing of patient information. By fully digitizing post-sample-preparation histopathology, it facilitates the streamlining of pathology workflows and enables the connectivity needed between multi-disciplinary teams and specialties when making complex cancer diagnosis and treatment decisions, from early detection and precision diagnosis through to precision treatment and predictable outcomes.

Ibex’s Galen platform adds AI-powered cancer detection, case prioritization, grading and other productivity-enhancing insights. Users have reported significant improvements in diagnostic efficiency, with 27% reduction in time-to-diagnosis compared to conventional microscope viewing, one to two-day reductions in total turnaround time, and 37% productivity gain. In addition to cancer, the AI platform supports pathologists in the accurate grading, as well as detection and diagnosis of multiple clinical features, such as tumor size, perineural invasion, high-grade PIN (Prostatic Intraepithelial Neoplasia) and more. The accuracy level of Galen Prostate for cancer detection was the highest level reported in the field, with a sensitivity rate of 98.46%, specificity of 97.33% and an AUC of 0.991. When used as an automated ‘second read,’ the platform alerts pathologists when discrepancies between their diagnosis and the AI algorithm’s findings are detected, providing a safety net against error or misdiagnosis, previously reported as high as 12%, and increasing overall quality of care.

Through breakthrough innovations and partnerships, Philips integrates intelligence and automation into its Precision Diagnosis portfolio, including smart diagnostic systems, integrated workflow solutions that transform departmental operations, advanced informatics that provides diagnostic confidence, and care pathway solutions that allow medical professionals to tailor treatment to individual patients. By developing and integrating these AI-enabled applications, the company aims to enhance the ability to turn data into actionable insights and drive the right care in the right sequence at the right time. The latest partnership announcement with Ibex follows recent AI partnership announcements with DiA Imaging Analysis for AI-powered ultrasound applications, and AI software provider Lunit, incorporating its chest detection suite into Philips diagnostic X-ray suite. These partner solutions complement Philips own AI solutions in personal health, precision diagnosis and treatment, and connected care.

“Building on our strong portfolio to support clinical decision-making in oncology, we bring together the power of imaging, pathology, genomics and longitudinal data with insights from artificial intelligence (AI) to help empower clinicians to deliver clear care pathways with predictable outcomes for every patient,” said Kees Wesdorp, Chief Business Leader, Precision Diagnosis at Philips. “By teaming with Ibex to incorporate their AI into our Digital Pathology Solutions, we’re further able to provide a continuous pathway, where critical patient data is made visible to both pathologists and oncologists to help improve the clinician experience and patient outcomes.”

“Pathology is transforming at an increasing pace and AI is one of the major drivers, supporting a more rapid and accurate cancer diagnosis,” said Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics. “By joining forces with Philips, the leader in digital pathology deployments, we can offer new end-to-end solutions enabling pathologists to implement integrated, AI-powered workflows across a broader segment of the diagnostic pathway, improving the quality of patient care and strengthening the business case for digitization.”





E-mail Print
FaceBook Twitter Google+ Linked in

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare with a strong presence in cardio-pulmonary, oncology and women’s health
More info

More articles about Philips Healthcare

09 Nov 2021
Philips Acquires Medical Technology Company Cardiologs to Expand Cardiac Diagnostics and Monitoring Portfolio
Royal Philips (Amsterdam, the Netherlands) has signed an agreement to acquire Cardiologs (Paris, France), a medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology.
Read More
09 Mar 2021
Philips' Diagnostic X-ray Suite to Incorporate Lunit's AI Software
Philips Healthcare (Amsterdam?, the Netherlands) has entered into a collaboration with Lunit (Seoul, Korea) that will make Lunit's AI software accessible to users of Philips' diagnostic X-ray solutions.
Read More
20 Jan 2021
Philips Acquires Capsule Technologies to Expand Leadership in Patient Care Management Solutions for Hospitals
Royal Philips (Amsterdam, the Netherlands) has signed an agreement to acquire Capsule Technologies, Inc. (Andover, MA, USA), a provider of medical device integration and data technologies for hospitals and healthcare organizations.
Read More
10 Mar 2020
Philips Receives Global AI for Enhanced Radiology Interpretation Company of The Year Award from Frost & Sullivan
 Philips Healthcare (Amsterdam?, Noord-Holland) has been recognized with the 2019 Global Company of the Year Award by Frost & Sullivan, based on its recent analysis of the global market for Artificial Intelligence (AI) for enhanced radiology interpretation market. Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Read More
05 Apr 2019
Philips Acquires Direct Radiology Teleradiology Platform
Royal Philips is expanding its radiology solutions portfolio with innovative teleradiology services, aimed at addressing the increasing shortage of radiologists, as well as the pressing need to improve access to precision diagnoses.
Read More
30 Oct 2018
Philips Launches Start-Up AI Collaboration Program
Royal Philips has launched its first global start-up collaboration program involving the company’s innovation hubs in Cambridge, US, Eindhoven, the Netherlands, Bangalore, India and Shanghai, China focused on the application of artificial intelligence (AI) in healthcare. The program focuses on the application of AI-based clinical decision support tools, such as image interpretation, analysis and integration, and workflow tools, such as intelligent treatment plans for radiology, ultrasound and oncology.
Read More
22 Aug 2018
Intel and Philips Partner to Speed Up Imaging Analysis Using AI
Intel Corporation and Royal Philips have tested two healthcare use cases for deep learning inference models: one on X-rays of bones for bone-age-prediction modeling and the other on CT scans of lungs for lung segmentation. In these tests, which were conducted using Intel Xeon Scalable processors and the OpenVINO toolkit, the researchers achieved a speed improvement of 188 times for the bone-age-prediction model and 38 times for the lung-segmentation model over the baseline measurements. These tests show that healthcare organizations can implement artificial intelligence (AI) workloads without expensive hardware investments.
Read More
25 Jun 2018
Philips Acquires Remote Diagnostic Technologies to Expand Therapeutics
Royal Philips has acquired Remote Diagnostic Technologies, which offers advanced solutions for the pre-hospital market providing monitoring, cardiac therapy and data management. RDT’s portfolio of connected emergency care solutions will complement Philips’ Therapeutic Care business and strengthen its leadership position in the resuscitation and emergency care market. RDT’s acquisition will also strengthen Philips’ ability to innovate, drive digital transformation in healthcare, and enter new markets.
Read More

Additional news

06 Dec 2021
IHF to Launch Geneva Centre of Healthcare Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) is preparing to launch the Geneva Centre of Healthcare Leadership for Sustainability (the Centre) in 2022 in response to the need for hospitals and healthcare services to address climate change.
Read More
06 Dec 2021
Global Mammography Market to Reach USD 3.4 Billion in 2028 Due To Increasing Prevalence of Breast Cancer
The global mammography market is expected to reach USD 3.4 billion in 2028, driven by the increasing prevalence of breast cancer across the globe, rising government fund for ongoing research on breast cancer, and increasing public awareness about cancer. The market growth is being fueled further by increasing number of screening programs and campaigns to create awareness about breast cancer, improving healthcare infrastructure and facilities, and technological advancements in breast imaging techniques.
Read More
03 Dec 2021
Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population
The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests by physicians, low price of tests, and awareness about complications of high diabetes levels.
Read More
02 Dec 2021
Roche Completes Acquisition of TIB Molbiol Group
Roche (Basel, Switzerland) has completed its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group (Berlin, Germany).
Read More
02 Dec 2021
Siemens Partners with Biotech Company Freenome to Develop Blood Test for Early Breast Cancer Detection
Siemens Healthineers (Erlangen, Germany) and Freenome (South San Francisco, CA, USA) have entered into a collaboration in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
Read More
01 Dec 2021
Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing
The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow assay kits, demand growth of point-of-care testing, and rise in adoption of LFA kits due to their advantages over laboratory tests.
Read More
30 Nov 2021
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market to Surpass USD 7.5 Billion by 2025
The global chemiluminescence immunoassay (CLIA) analyzers market is estimated to grow at a CAGR of 6.4% in the forecast period of 2020-2025 to reach USD 7.6 billion by 2025, with the reagents segment anticipated to capture almost three-fourth of the overall CLIA analyzers market and reach USD 5.7 billion by the end of 2025.
Read More
29 Nov 2021
Global Fluoroscopy Equipment Market to Top USD3.5 Billion by 2031 Due to Demand for Multipurpose Imaging Tools
The global fluoroscopy equipment market is projected to grow at a CAGR of 6% from an estimated USD 1.9 billion in 2021 to surpass USD 3.5 billion by the end of 2031, driven by surging applications of fluoroscopy equipment across various medical fields such as cardiology, nephrology, urology, and others.
Read More
25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions